Knowledge Home Human Health Knowledge All Opinion Papers Popular science Interviews Filter Therapeutic areasCOVID-19Digestive health Apply Home Human Health Knowledge Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax®) by HIPRA Home Human Health Knowledge Safety and immunogenicity of a PHH-1V booster dose after different prime vaccination schemes against COVID-19: Phase III clinical trial final results up to one year Home Human Health Knowledge Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results Home Human Health Knowledge Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months Home Human Health Knowledge Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial Home Human Health Knowledge Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2 Home Human Health Knowledge Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate Home Human Health Knowledge Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates Home Human Health Knowledge RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine? Load more
